



---

## P R E S S   R E L E A S E

---

### **Ypsomed ties up with Lupin to supply YpsoPen® for India**

**Burgdorf, 5 May 2015, 7:00 a.m. – Ypsomed has entered into an exclusive agreement to supply Indian pharmaceutical major Lupin Limited (Lupin) with its reusable and affordable YpsoPen®. The YpsoPen® would be used to administer Lupin's insulin.**

As the third-largest Indian pharmaceutical company with strong growth and over 45 years of market experience, Lupin is intimately acquainted with the Indian market and the needs of patients with diabetes in India. As such, Lupin is an ideal strategic partner for the Swiss injection system manufacturer Ypsomed. According to current estimates by the International Diabetes Federation (IDF), over 65 million people in India have diabetes. By 2030, the number is even expected to increase to over 100 million.

Ypsomed, for its part, is very pleased to be expanding the relationship with the Indian pharmaceutical company, since Lupin has once again selected an injection system from Ypsomed. Ypsomed has been supplying ServoPen®, Ypsomed's spring driven high-end injection pen, to Lupin since 2013.

For further information, please contact Benjamin Overney, Head of Investor & Public Relations at Ypsomed Holding AG, by phone at +41 34 424 41 59 or by email ([benjamin.overney@ypsomed.com](mailto:benjamin.overney@ypsomed.com)).



### **About Lupin Limited**

Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded and generic formulations as well as biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership positions in the Anti-TB and Cephalosporin segment. Lupin is the 5th largest and fastest growing top 5 generics player in the US (5.3% market share by prescriptions, IMS Health) and the 3rd largest Indian pharmaceutical company by sales. The Company is also amongst the top 10 generic pharmaceutical players in Japan and South Africa (IMS). For the financial year ended March 2014, Lupin's Consolidated revenues and Profit after tax were Rs. 110,866 million (USD 1.83 billion) and Rs. 18,364 million (USD 304 million) respectively.

Please visit <http://www.lupin.com> for more information. You could also follow Lupin on Twitter – [www.twitter.com/lupinlimited](http://www.twitter.com/lupinlimited)

### **About the Ypsomed Group**

The Ypsomed Group is the leading developer and manufacturer of injection systems for self-medication and a renowned diabetes specialist with 30 years of experience. Founded in 2003 from the well-known company Disetronic Medical Systems, today it offers insulin pumps and injection systems as well as pen needles for the treatment of diabetes, growth disorders, infertility, oncology and other therapeutic areas. Ypsomed is regarded as a leader in innovation and technology and is the preferred partner of pharmaceutical and biotech companies in the self-medication field. Ypsomed has established itself with the umbrella brands mylife™ Diabetescare and YDS™ Ypsomed Delivery Systems in retailing and in business-to-business trading respectively. Under the brand name mylife™ Diabetescare, Ypsomed offers patients an extensive range of self-manufactured products or commercial products for the treatment of diabetes. The range from YDS™ reflects the many years of experience and competence in the field of injection systems. With an innovative and patent-protected product portfolio of pen systems and autoinjectors, which can be adapted to customer requirements, and contract development and manufacturing, Ypsomed provides customer orientated product and service solutions to pharmaceutical and biotech companies worldwide. Ypsomed has its headquarters in Burgdorf in Switzerland and owns several manufacturing sites in Switzerland and in the Czech Republic. Ypsomed has its own subsidiaries throughout Europe and works with leading, independent marketing partners worldwide. The Ypsomed Group has around 1,100 employees.